ASSESSMENT of THYROID FUNCTION and ANATOMY with TECHNETIUM-99M AS PERTECHNETATE

Total Page:16

File Type:pdf, Size:1020Kb

ASSESSMENT of THYROID FUNCTION and ANATOMY with TECHNETIUM-99M AS PERTECHNETATE ASSESSMENT OF THYROID FUNCTION AND ANATOMY WITH TECHNETIUM-99m AS PERTECHNETATE Harold 1. Atkins and Powell Richards Brookhaven National Laboratory, Upton, New York A number of elements other than iodine are se The patient was placed supine, and a suitably lectively concentrated by the thyroid gland (1—7). collimated 2 x 2-in. NaI(Tl) crystal scintillation de Among these are elements in the periodic group tector was placed over the neck 25 cm from the skin VIIa (manganese, technetium and rhenium) which surface. The detector signal was fed through a dis are taken up by the thyroid gland but, in contra criminator and ratemeter to a strip-chart paper distinction to iodine, are not organically bound. recorder. The radioactivity in the neck was con Technetium is not a naturally occuring element tinuously recorded after the intravenous administra and exists only in radioactive form. One of the iso tion of 2.0—2.6mc [email protected] amount topes of technetium is o9mTc which is available as of activity, which is suitable for scintillation scanning, the daughter product of 99Mo in a generator system produced counting rates too high for a flat-field (8). Its physical characteristics make it particularly collimator. Therefore 2.5 cm of Lucite were inserted suitable for scintillation scanning; it has a short half over the end of the detector collimator which reduced life of 6 hr, virtually no beta emission and a mod the sensitivity by 30% and eliminated errors due to erately low-energy gamma emission ( 140 key) that the resolving-time capability of the detector. The can be efficiently collimated. The possibility of ad settings were : 300,000 counts/min scale, 1-sec time ministering millicurie quantities of activity without constant and 12-in./hr paper speed. delivering a high radiation dose to the patient allows After the initial peak caused by the bolus of studies to be performed rapidly and accurately. Be activity passing through the neck and great vessels, cause of these characteristics, the isotope has been the counting rate dropped rapidly to a minimum widely used as a scanning agent (9—11). value within 1 mm after injection. There was then a Because the uptake of technetium in the thyroid gradual rise in counting rate over the next 15—20 reflects the state of the trapping function of the mm to a maximumvalue. The countingrate then gland, its use in studying thyroid physiology has been remained fairly constant with only a slow diminution suggested (12,13 ) . It is the purpose of this study (Fig. 1) . A “trappingindex―was determined by to evaluate the thyroidal uptake of o9mTc@pertechne@dividing the minimum counting rate into the maxi tate in relation to the clinical state and to make an mum. An “accumulation gradient― was determined intercomparison with other tests of thyroid function. by measuring the average slope of the curve from Several parameters of technetium uptake have been the minimum to the half-maximum value. A modifi measured and correlated with each other as well as cation was introduced after the study had been started with the results of @@1Juptake and serum protein which reduced the size of the initial “spike―of activity bound iodine. so that the recording needle would not go off scale. A %6-in. lead sheet was placed over the neck and METHOD upper chest with an opening 4-in. in diameter over The patients included referrals from the Industrial the thyroid area. This sheet reduced extraneous Medicine Clinic at the Medical Research Center, counts from activity in the heart and great vessels. Brookhaven, patients hospitalized at the Medical After recording over the neck, a recording was Research Center primarily for other reasons than made over the thigh for 1 mm. When this value was disturbances of the thyroid and referrals from sev subtracted from the maximum and minimum values, era! outside physicians who questioned abnormal thyroid function or the presence of palpable nodules. Received Nov. 9, 1966; revision accepted April 4, 1967. Volume 9, Number 1 7 ATKINS AND RICHARDS The vial, made of 1.5-mm-thick Lucite, was inserted into a Lucite cylindrical neck phantom 1 2.7 cm in diameter and 12.7 cm high. The center of the vial (J@ I— was 2.2 cm from the anterior surface of the neck z 0 phantom (Fig. 2). 0 w We performed a scan of the phantom immediately > after completing the patient study using the same -J parameters. The uptake of 9amTc in the gland was U then determined by counting dots on the teledeltos recording over the thyroid, subtracting background and comparing the results with the standard that con tamed 3 % of the injected activity (Fig. 3 ) . This method is similar to that of Andros et al (12 ) , but we made no corrections for size and depth of the gland because these estimates have a high degree of error, and we felt that the phantom represented a good average. The determination of thyroidal uptake TIME using the “dot―scan is more accurate than the usual FIG.1. Immediateuptakeof°@mTc-pertechnetateinthyroidafter method because of the rather low uptake of tech intravenousinjection.Traceproceedsintimefromrighttoleft. netium in the thyroid and the high background level Traces are on individuals with hyperthyroidism (middle), normal function (above) and hypothyroidism (below). of radioactivity, including localization in salivary glands. Nearly all patients had a PBI determination on a “corrected trapping index― was determined. It had the day of the B9mTcstudy. If it was not inconvenient been determined previously that the activity level for the patient, an oral dose of 131!was administered over the thigh did not change during this time interval. after the scan was completed, and a 24-hr uptake A neck-to-thigh ratio was also computed. in the thyroid was determined. The BBmTcdid not When these steps were completed (about 15—20 interfere with this study because the activity level mm) , the patient was placed under a rectilinear had decreased by a factor of I 6 in 24 hr, about 30% scanner (Picker Magnascanner, 3 x 2-in. NaI(Tl) had been excreted and the discriminator setting of crystal) , and the isotope distribution in the neck the detector effectively eliminated the 140-key pho was determined. Focusing collimators with I ,045 tons. Special studies, such as a BE! or a T-3 resin holes, developed in the Brookhaven Hot Laboratory, uptake, were performed as indicated. are used for scanning (14) . Depending on the count In 47 patients the following procedure was used: ing rate, one of the two collimator thicknesses is A sample of blood was drawn at the end of the scan, used. The most often used is a I .3-in. collimator with a resolution of 0.16 in. (4 mm) at the 50% isoresponse level and 3.5-in. focal depth. When the counting rate is low, as in hypothyroidism or after suppression by exogenous thyroid medication, a 1-in. collimator is used. Its resolution is 0.23 in. (6 mm), but the sensitivity is about 40% greater. Maximum counting rates over the thyroid ranged from 20,000 to 40,000 counts/mm for euthyroid patients. Scan ning speeds of 30—50 cm/mm with indexing steps of 0. 15 cm are the usual scanning parameters. These provide a maximum counting rate density of 3,750— 5,625 per square centimeter. The duration of the scan was 5—15mm. c A standard was prepared in the following way. A quantity of 99―Tcequivalent to that injected into the patient (0.3—0.7 ml) was diluted to 100 ml. Three milliliters of this standard were then added to 20 ml of water in a Lucite vial cylinder with an FIG.2. Luciteneckphantomandvialrepresentingthyroidare inner diameter of 2.3 cm and a length of 6.3 cm. used for determining thyroid accumulation of @@mTc. 8 JOURNAL OF NUCLEAR MEDICINE @ : J 0:: ; @: e C C C C • C C V S 4 C • C C • C C C a * C C C C C C S S . C S I C C C S C C C C b S S S S • e a C 0 5 5 C S a C S C 0 5 S C S S C C S C S @ C C C S C S S C • •@S S S • C S C C • C e C C C • C • • • S C S C C S S S C C a a a a . S 4 C S S C C @ S C C C . S • S a C S S S S a S • S S S S C S C S L • S S C C C C a . tc@ FIG.3. Exampleofcalculationofthy. roidal concentration of @@mTcfrom tele = deltos scans of neck and phantom. Back ground is measured in rectangular region @ and multiplied by 8 to compensate for st@0@Z&@L2,o7xz difference in area. d.f. refers to dot scaling @ factor used in making scan. 1'@@i@@.;&tt@,t&b;L:I ;‘@.i:@7@ and the 99mTcactivity per milliliter of plasma was pothyroidism were studied, and they all had uptakes determined. The size of the thyroid was calculated below 0.5% . In the diagnosis of the hyperthyroid from the scan using the method developed by Good state, two of I 5 patients whose thyroids were defi win et a! ( 15), and the ratio [TcO;] thyroid/[TcO4@] nitely overactive had technetium uptakes below , plasma as well as the thyroidal technetium space 4.0% for a diagnostic accuracy of 87%.
Recommended publications
  • Novel Application of Quantitative Single-Photon Emission Computed
    Original Article | Nuclear Medicine https://doi.org/10.3348/kjr.2017.18.3.543 pISSN 1229-6929 · eISSN 2005-8330 Korean J Radiol 2017;18(3):543-550 Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves’ Disease Hyun Joo Kim, MD1, 2, Ji-In Bang, MD1, Ji-Young Kim, MD, PhD1, Jae Hoon Moon, MD, PhD3, Young So, MD, PhD4, Won Woo Lee, MD, PhD1, 5 Departments of 1Nuclear Medicine and 3Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea; 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Suwon 16229, Korea; 4Department of Nuclear Medicine, Konkuk University Medical Center, Seoul 05030, Korea; 5Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 08826, Korea Objective: Since Graves’ disease (GD) is resistant to antithyroid drugs (ATDs), an accurate quantitative thyroid function measurement is required for the prediction of early responses to ATD. Quantitative parameters derived from the novel technology, single-photon emission computed tomography/computed tomography (SPECT/CT), were investigated for the prediction of achievement of euthyroidism after methimazole (MMI) treatment in GD. Materials and Methods: A total of 36 GD patients (10 males, 26 females; mean age, 45.3 ± 13.8 years) were enrolled for this study, from April 2015 to January 2016. They underwent quantitative thyroid SPECT/CT 20 minutes post-injection of 99mTc- pertechnetate (5 mCi). Association between the time to biochemical euthyroidism after MMI treatment and %uptake, standardized uptake value (SUV), functional thyroid mass (SUVmean x thyroid volume) from the SPECT/CT, and clinical/ biochemical variables, were investigated.
    [Show full text]
  • Thyroid Disease Update
    10/11/2017 Thyroid Disease Update • Donald Eagerton M.D. Disclosures I have served as a clinical investigator and/or speakers bureau member for the following: Abbott, Astra Zenica, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, and Sanofi Aventis Thyroid Disease Update • Hypothyroidism • Hyperthyroidism • Thyroid Nodules • Thyroid Cancer 1 10/11/2017 2 10/11/2017 Case 1 • 50 year old white female is seen for follow up. Notices cold intolerance, dry skin, and some fatigue. Cholesterol is higher than prior visits. • Family history; Mother had history of hypothyroidism. Sister has hypothyroidism. • TSH = 14 (0.30- 3.3) Free T4 = 1.0 (0.95- 1.45) • Weight 70 kg Case 1 • Next step should be • A. Check Free T3 • B. Check AntiMicrosomal Antibodies • C. Start Levothyroxine 112 mcg daily • D. Start Armour Thyroid 30 mg q day • E. Check Thyroid Ultrasound Case 1 Next step should be • A. Check Free T3 • B. Check AntiMicrosomal Antibodies • C. Start Levothyroxine 112 mcg daily • D. Start Armour Thyroid 30 mg q day • E. Check Thyroid Ultrasound 3 10/11/2017 Hypothyroidism • Incidence 0.1- 2.0 % of the population • Subclinical hypothyroidism in 4-10% of the adult population • 5-8 times higher in women An FT4 test can confirm hypothyroidism 13 • In the presence of high TSH and FT4 levels in relation to the thyroid function TSH, low FT4 (free thyroxine) usually signalsTSH primary hypothyroidism12 Overt Mild Mild Overt Euthyroidism FT4 Hypothyroidism Thyrotoxicosis* Thyrotoxicosis vs. hyperthyroidism¹ While these terms are often used interchangeably, thyrotoxicosis (toxic thyroid), describes presence of too much thyroid hormone, whether caused by thyroid overproduction (hyperthyroidism); by leakage of thyroid hormone into the bloodstream (thyroiditis); or by taking too much thyroid hormone medication.
    [Show full text]
  • Clinical Thyroidology for Patients Volume 6 Issue 8 2013
    Clinical THYROIDOLOGY th 90 ANNIVERSARY FOR PATIENTS VOLUME 6 ISSUE 8 2013 www.thyroid.org EDITOR’S COMMENTS . .2 Tanda ML et al Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed HYPOTHYROIDISM . 3 Graves’ hyperthyroidism seen at a single center. J Clin Desiccated thyroid extract vs Levothyroxine Endocrinol Metab 2013;98:1443-9. in the treatment of hypothyroidism Levothyroxine is the most common form of thyroid hormone THYROID CANCER . 8 replacement therapy. Prior to the availability of the pure levothy- Stimulated thyroglobulin levels obtained after roxine, desiccated animal thyroid extract was the only treatment thyroidectomy are a good indicator for risk of for hypothyroidism and some individuals still prefer dessicated future recurrence from thyroid cancer. thyroid extract as a more “natural” thyroid hormone. This study Thyroglobulin is a protein secreted only by thyroid cells, both was performed to compare levothyroxine to desiccated thyroid normal and cancerous thyroid cells. After thyroidectomy and extract in terms of thyroid blood tests, changes in weight, psy- removal of most of the normal thyroid cells, blood thyroglobu- chometric test results and patient preference. lin levels are used to detect thyroid cancer recurrence. In this Hoang TD et al Desiccated thyroid extract compared study, the authors examined the ability of thyroglobulin levels with levothyroxine in the treatment of hypothyroidism: measured after initial thyroidectomy to accurately predict the A randomized, double-blind, crossover study. J Clin Endo- chance for future thyroid cancer recurrence in high risk patients. crinol Metab 2013;98:1982-90. Epub March 28, 2013. Piccardo, A.
    [Show full text]
  • Fate of Sodium Pertechnetate-Technetium-99M
    JOURNAL OF NUCLEAR MEDICINE 8:50-59, 1967 Fate of Sodium Pertechnetate-Technetium-99m Dr. Muhammad Abdel Razzak, M.D.,1 Dr. Mahmoud Naguib, Ph.D.,2 and Dr. Mohamed El-Garhy, Ph.D.3 Cairo, Egypt Technetium-99m is a low-energy, short half-life iostope that has been recently introduced into clinical use. It is available as the daughter of °9Mowhich is re covered as a fission product or produced by neutron bombardement of molyb denum-98. The aim of the present work is to study the fate of sodium pertechnetate 9OmTc and to find out any difference in its distribution that might be caused by variation in the method of preparation of the parent nuclide, molybdenum-99. MATERIALS & METHODS The distribution of radioactive sodium pertechnetate milked from 99Mo that was obtained as a fission product (supplied by Isocommerz, D.D.R.) was studied in 36 white mice, weighing between 150 and 250 gm each. Normal isotonic saline was used for elution of the pertechnetate from the radionuclide generator. The experimental animals were divided into four equal groups depending on the route of administration of the radioactive material, whether intraperitoneal, in tramuscular, subcutaneous or oral. Every group was further subdivided into three equal subgroups, in order to study the effect of time on the distribution of the pertechnetate. Thus, the duration between administration of the radio-pharma ceutical and sacrificing the animals was fixed at 30, 60 and 120 minutes for the three subgroups respectively. Then the animals were dissected and the different organs taken out.Radioactivityin an accuratelyweighed specimen from each organ was estimated in a scintillation well detector equipped with one-inch sodium iodide thallium activated crystal.
    [Show full text]
  • Package Insert TECHNETIUM Tc99m GENERATOR for the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceuti
    NDA 17693/S-025 Page 3 Package Insert TECHNETIUM Tc99m GENERATOR For the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceutical For intravenous use only Rx ONLY DESCRIPTION The technetium Tc99m generator is prepared with fission-produced molybdenum Mo99 adsorbed on alumina in a lead-shielded column and provides a means for obtaining sterile pyrogen-free solutions of sodium pertechnetate Tc99m injection in sodium chloride. The eluate should be crystal clear. With a pH of 4.5-7.5, hydrochloric acid and/or sodium hydroxide may have been used for Mo99 solution pH adjustment. Over the life of the generator, each elution will provide a yield of > 80% of the theoretical amount of technetium Tc99m available from the molybdenum Mo99 on the generator column. Each eluate of the generator should not contain more than 0.0056 MBq (0.15 µCi) of molybdenum Mo99 per 37 MBq, (1 mCi) of technetium Tc99m per administered dose at the time of administration, and not more than 10 µg of aluminum per mL of the generator eluate, both of which must be determined by the user before administration. Since the eluate does not contain an antimicrobial agent, it should not be used after twelve hours from the time of generator elution. PHYSICAL CHARACTERISTICS Technetium Tc99m decays by an isomeric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging studies is listed in Table 1. Table 1. Principal Radiation Emission Data1 Radiation Mean %/Disintegration Mean Energy (keV) Gamma-2 89.07 140.5 1Kocher, David C., “Radioactive Decay Data Tables,” DOE/TIC-11026, p.
    [Show full text]
  • MEDICATION GUIDE PROPYLTHIOURACIL (Pro-Pil-Thi-O-Ur-A-Sil) Tablets Read This Medication Guide Before You Start Taking Propylthiouracil and Each Time You Get a Refill
    MEDICATION GUIDE PROPYLTHIOURACIL (Pro-pil-thi-o-ur-a-sil) Tablets Read this Medication Guide before you start taking Propylthiouracil and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. What is the most important information I should know about Propylthiouracil? Propylthiouracil can cause serious side effects, including: • Severe liver problems. In some cases, liver problems can happen in people who take Propylthiouracil including: liver failure, the need for liver transplant, or death. Stop taking Propylthiouracil and call your doctor right away if you have any of these symptoms: • fever • loss of appetite •nausea • vomiting • tiredness • itchiness • pain or tenderness in your right upper stomach area (abdomen) • dark (tea colored) urine • pale or light colored bowel movements (stools) • yellowing of your skin or whites of your eyes • Serious risks during pregnancy. Propylthiouracil may cause liver problems, liver failure and death in pregnant women and may harm your unborn baby. Propylthiouracil may also cause liver problems or death of infants born to women who take Propylthiouracil during certain trimesters of pregnancy. Propylthiouracil may be used when an antithyroid drug is needed during or just before the first trimester of pregnancy. If you get pregnant while taking Propylthiouracil, call your doctor right away about your therapy. What is Propylthiouracil? Propylthiouracil is a prescription medicine used to treat people who have Graves’ disease with hyperthyroidism or toxic multinodular goiter. Propylthiouracil is used when: • certain other antithyroid medicines do not work well. • thyroid surgery or radioactive iodine therapy is not a treatment option.
    [Show full text]
  • Loss of Pertechnetate from the Human Thyroid
    LOSS OF PERTECHNETATE FROM THE HUMAN THYROID J. G. Shimmins Regional Dept. of Clinical Physics and Bioengineering, Western Regional Hospital Board, Glasgow, Scotland R. McG. Harden and W. D. Alexander University Department of Medicine, Western Infirmary, Glasgow, Scotland The pertechnetate ion, like the iodide ion, is Magnascanner V (3,6) were started immediately trapped by the thyroid gland (1 ). Several authors after injection and were continued for 45 mm when have claimed that pertechnetate is not bound in the five scans had normally been completed. The scan thyroid (2) and that the gland behaves as a single speed was 100 cm/sec, and the line spacing was compartment (3) . However, the finding of organic 1 cm. Venous blood samples were taken at 2, 8, 15, binding of 9DmTcin rats (4,5) raises the question 30 and 45 mm. One gram perchlorate was given of whether some such binding may not occur in man. orally as a crushed powder in nine subjects 50 mm In this study we have investigated the binding of after the intravenous administration of pertechne pertechnetate in the human gland by measuring the tate. The same amount was given orally to the re rate of pertechnetate discharge from it after per maining four 3 hr after intravenous administra chlorate administration and have compared this rate tion of pertechnetate. Scans were carried out for an of discharge with the normal loss rate of pertechne additional 45 min after perchlorate administration, tate from the thyroid (3). If pertechnetate is Un and blood samples were taken at 2, 8, 15 and 45 bound, it should be possible to discharge it from min.
    [Show full text]
  • Radionuclide Thyroid Scans
    Radionuclide Thyroid Scans Report 2003 1 Purpose The purpose of this guideline is to assist specialists in Nuclear Medicine and Radionuclide Radiology in recommending, performing, interpreting and reporting radionuclide thyroid scans. This guideline will assist individual departments in the formulation of their own local protocols. Background Thyroid scintigraphy is an effective imaging method for assessing the functionality of thyroid lesions including the uptake function of part or all of the thyroid gland. 99TCm pertechnetate is trapped by thyroid follicular cells. 123I-Iodide is both trapped and organified by thyroid follicular cells. Common Indications 1.1 Assessment of functionality of thyroid nodules. 1.2 Assessment of goitre including hyperthyroid goitre. 1.3 Assessment of uptake function prior to radio-iodine treatment 1.4 Assessment of ectopic thyroid tissue. 1.5 Assessment of suspected thyroiditis 1.6 Assessment of neonatal hypothyroidism Procedure 1 Patient preparation 1.1 Information on patient medication should be obtained prior to undertaking study. Patients on Thyroxine (Levothyroxine Sodium) should stop treatment for four weeks prior to imaging, patients on Tri-iodothyronine (T3) should stop treatment for two weeks if adequate images are to be obtained. 1.2 All relevant clinical history should be obtained on attendance, including thyroid medication, investigations with contrast media, other relevant medication including Amiodarone, Lithium, kelp, previous surgery and diet. 1.3 All other relevant investigations should be available including results of thyroid function tests and ultrasound examinations. 1.4 Studies should be scheduled to avoid iodine-containing contrast media prior to thyroid imaging. 2 1.5 Carbimazole and Propylthiouracil are not contraindicated in patients undergoing 99Tcm pertechnetate thyroid scans and need not be discontinued prior to imaging.
    [Show full text]
  • Neo-Mercazole
    NEW ZEALAND DATA SHEET 1 NEO-MERCAZOLE Carbimazole 5mg tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5mg of carbimazole. Excipients with known effect: Sucrose Lactose For a full list of excipients see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM A pale pink tablet, shallow bi-convex tablet with a white centrally located core, one face plain, with Neo 5 imprinted on the other. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Primary thyrotoxicosis, even in pregnancy. Secondary thyrotoxicosis - toxic nodular goitre. However, Neo-Mercazole really has three principal applications in the therapy of hyperthyroidism: 1. Definitive therapy - induction of a permanent remission. 2. Preparation for thyroidectomy. 3. Before and after radio-active iodine treatment. 4.2 Dose and method of administration Neo-Mercazole should only be administered if hyperthyroidism has been confirmed by laboratory tests. Adults Initial dosage It is customary to begin Neo-Mercazole therapy with a dosage that will fairly quickly control the thyrotoxicosis and render the patient euthyroid, and later to reduce this. The usual initial dosage for adults is 60 mg per day given in divided doses. Thus: Page 1 of 12 NEW ZEALAND DATA SHEET Mild cases 20 mg Daily in Moderate cases 40 mg divided Severe cases 40-60 mg dosage The initial dose should be titrated against thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism. Three factors determine the time that elapses before a response is apparent: (a) The quantity of hormone stored in the gland. (Exhaustion of these stores usually takes about a fortnight).
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ultra-TechneKow FM 2.15-43.00 GBq radionuclide generator 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium pertechnetate (99mTc) injection is produced by means of a (99Mo/99mTc) generator. Technetium (99mTc) decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.01 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable. The radionuclide generator containing the parent isotope 99Mo, adsorbed on a chromatographic column delivers sodium pertechnetate (99mTc) injection in sterile solution. The 99Mo on the column is in equilibrium with the formed daughter isotope 99mTc. The generators are supplied with the following 99Mo activity amounts at activity reference time which deliver the following technetium (99mTc) amounts, assuming a 100% theoretical elution yield and 24 hours time from previous elution and taking into account that branching ratio of 99Mo is about 87%: 99mTc activity (maximum theoretical elutable 1.90 3.81 5.71 7.62 9.53 11.43 15.24 19.05 22.86 26.67 30.48 38.10 GBq activity at ART, 06.00 h CET) 99Mo activity (at ART, 06.00 h 2.15 4.30 6.45 8.60 10.75 12.90 17.20 21.50 25.80 30.10 34.40 43.00 GBq CET) The technetium (99mTc) amounts available by a single elution depend on the real yields of the kind of generator used itself declared by manufacturer and approved by National Competent Authority.
    [Show full text]
  • Management of Hyperthyroidism During Pregnancy and Lactation
    European Journal of Endocrinology (2011) 164 871–876 ISSN 0804-4643 REVIEW Management of hyperthyroidism during pregnancy and lactation Fereidoun Azizi and Atieh Amouzegar Research Institute for Endocrine Sciences, Endocrine Research Center, Shahid Beheshti University (MC), PO Box 19395-4763, Tehran 198517413, Islamic Republic of Iran (Correspondence should be addressed to F Azizi; Email: [email protected]) Abstract Introduction: Poorly treated or untreated maternal overt hyperthyroidism may affect pregnancy outcome. Fetal and neonatal hypo- or hyper-thyroidism and neonatal central hypothyroidism may complicate health issues during intrauterine and neonatal periods. Aim: To review articles related to appropriate management of hyperthyroidism during pregnancy and lactation. Methods: A literature review was performed using MEDLINE with the terms ‘hyperthyroidism and pregnancy’, ‘antithyroid drugs and pregnancy’, ‘radioiodine and pregnancy’, ‘hyperthyroidism and lactation’, and ‘antithyroid drugs and lactation’, both separately and in conjunction with the terms ‘fetus’ and ‘maternal.’ Results: Antithyroid drugs are the main therapy for maternal hyperthyroidism. Both methimazole (MMI) and propylthiouracil (PTU) may be used during pregnancy; however, PTU is preferred in the first trimester and should be replaced by MMI after this trimester. Choanal and esophageal atresia of fetus in MMI-treated and maternal hepatotoxicity in PTU-treated pregnancies are of utmost concern. Maintaining free thyroxine concentration in the upper one-third of each trimester-specific reference interval denotes success of therapy. MMI is the mainstay of the treatment of post partum hyperthyroidism, in particular during lactation. Conclusion: Management of hyperthyroidism during pregnancy and lactation requires special considerations andshouldbecarefullyimplementedtoavoidanyadverse effects on the mother, fetus, and neonate. European Journal of Endocrinology 164 871–876 Introduction hyperthyroidism during pregnancy is of utmost import- ance.
    [Show full text]
  • Management of Graves Disease:€€A Review
    Clinical Review & Education Review Management of Graves Disease A Review Henry B. Burch, MD; David S. Cooper, MD Author Audio Interview at IMPORTANCE Graves disease is the most common cause of persistent hyperthyroidism in adults. jama.com Approximately 3% of women and 0.5% of men will develop Graves disease during their lifetime. Supplemental content at jama.com OBSERVATIONS We searched PubMed and the Cochrane database for English-language studies CME Quiz at published from June 2000 through October 5, 2015. Thirteen randomized clinical trials, 5 sys- jamanetworkcme.com and tematic reviews and meta-analyses, and 52 observational studies were included in this review. CME Questions page 2559 Patients with Graves disease may be treated with antithyroid drugs, radioactive iodine (RAI), or surgery (near-total thyroidectomy). The optimal approach depends on patient preference, geog- raphy, and clinical factors. A 12- to 18-month course of antithyroid drugs may lead to a remission in approximately 50% of patients but can cause potentially significant (albeit rare) adverse reac- tions, including agranulocytosis and hepatotoxicity. Adverse reactions typically occur within the first 90 days of therapy. Treating Graves disease with RAI and surgery result in gland destruction or removal, necessitating life-long levothyroxine replacement. Use of RAI has also been associ- ated with the development or worsening of thyroid eye disease in approximately 15% to 20% of patients. Surgery is favored in patients with concomitant suspicious or malignant thyroid nodules, coexisting hyperparathyroidism, and in patients with large goiters or moderate to severe thyroid Author Affiliations: Endocrinology eye disease who cannot be treated using antithyroid drugs.
    [Show full text]